Phase III trial comparing 3–6 months of adjuvant FOLFOX4/XELOX in stage II–III colon cancer: safety and compliance in the TOSCA trialSara Lonardi, Maria Di Bartolomeo, Monica Ronzoni et al.|Annals of Oncology|2016Cited by 56
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trialGerardo Rosati, Giordano Beretta, Sara Lonardi et al.|European Journal of Cancer|2021Cited by 15